Aerovate Therapeutics, Inc. (AVTE)
- Previous Close
18.90 - Open
18.68 - Bid 18.20 x 100
- Ask 18.59 x 200
- Day's Range
17.50 - 18.90 - 52 Week Range
9.41 - 32.42 - Volume
123,717 - Avg. Volume
191,934 - Market Cap (intraday)
529.929M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-3.03 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.67
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
aerovatetx.comRecent News: AVTE
Performance Overview: AVTE
Trailing total returns as of 6/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVTE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVTE
Valuation Measures
Market Cap
544.48M
Enterprise Value
445.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.99
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.78%
Return on Equity (ttm)
-80.58%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-82.19M
Diluted EPS (ttm)
-3.03
Balance Sheet and Cash Flow
Total Cash (mrq)
99.33M
Total Debt/Equity (mrq)
0.85%
Levered Free Cash Flow (ttm)
-39M
Research Analysis: AVTE
Company Insights: AVTE
AVTE does not have Company Insights